Net Prices Of Four Biologics All Decreased In Face Of Competition From Biosimilars, Other Substitutes, Even Without Interchangeability, Research Indicates

The net prices of four biologics – filgrastim, pegfilgrastim, infliximab and insulin glargine – all decreased in the face of competition from biosimilars or other substitutes, even without interchangeability,” investigators found after studying “pricing data from SSR Health,” which, “according to the researchers...provides estimates of list prices, net prices, Medicaid discounts and discounts regarding other payers for branded products with the United States, as reported by publicly traded companies.” For the study, researchers focused on “the time period from January 2007 to June 2018,” defining “quarterly net prices as the ratio between sales and the number of units sold, while discounts were calculated as the ratio between the difference in list and net prices and the list prices.” The findings were published online in a research letter in JAMA Network Open. https://www.healio.com/rheumatology/practice-management/news/online/%7Ba2441bb6-4163-4c0f-a7e5-8ac517f660fe%7D/biologics-net-prices-decrease-with-biosimilar-competition